Projected inhibition of platelet aggregation with ticagrelor twice dailyvs.clopidogrel once daily based on patient adherence data (the TWICE project)
出版年份 2013 全文链接
标题
Projected inhibition of platelet aggregation with ticagrelor twice dailyvs.clopidogrel once daily based on patient adherence data (the TWICE project)
作者
关键词
-
出版物
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 77, Issue 5, Pages 746-755
出版商
Wiley
发表日期
2013-11-01
DOI
10.1111/bcp.12275
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial
- (2013) Jean-Jacques Parienti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A new taxonomy for describing and defining adherence to medications
- (2012) Bernard Vrijens et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients
- (2012) Jean-Luc Reny et al. CIRCULATION
- Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease
- (2012) Steen E. Husted et al. CLINICAL PHARMACOKINETICS
- Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients
- (2012) R M Savic et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of dosing frequency on chronic cardiovascular disease medication adherence
- (2012) Craig I. Coleman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment
- (2012) H. Boden et al. JOURNAL OF INTERNAL MEDICINE
- Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories
- (2011) Terrence F. Blaschke et al. Annual Review of Pharmacology and Toxicology
- Antiplatelet therapy in acute coronary syndromes
- (2011) Alberto Menozzi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Advances in Antiplatelet Therapy
- (2011) A. D. Michelson Hematology-American Society of Hematology Education Program
- Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers
- (2010) Kathleen Butler et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
- (2010) Paul A. Gurbel et al. CIRCULATION
- Understanding Forgiveness: Minding and Mining the Gaps Between Pharmacokinetics and Therapeutics
- (2010) L G Osterberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
- (2010) Renli Teng et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
- (2010) Lars Wallentin et al. LANCET
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease
- (2009) Paul A. Gurbel et al. CIRCULATION
- Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements
- (2009) Joseph M. Sweeny et al. Nature Reviews Cardiology
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
- (2008) Anna Maria Gori et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started